He is accusing GSK, formerly known as GlaxoSmithKline, of hiding the cancer risks of its once-popular heartburn drug, Zantac. Yost filed a motion on Monday requesting that the Ohio Public Employees ...

Investors and analysts are only now starting to pay serious attention to GSK's potential historical liabilities relating to Zantac (ranitidine). GSK has been named as a defendant in approximately ...

Pfizer Inc (NYSE:PFE) has reportedly settled 10,000 lawsuits alleging it concealed the cancer risks associated with its Zantac heartburn medication, marking the largest resolution in the litigation.

The initial U.S. court trial concerning the antacid medication Zantac is slated to commence on November 13 in a state court in California, as stated by a lawyer representing the plaintiffs. The ...

Shares of drugmakers Sanofi, GlaxoSmithKline (GSK), Haleon and Pfizer have taken a hit this week in response to investors' growing fears about litigation related to the recalled heartburn drug Zantac.

Even though drugs have different effects on different individuals, research reveals that Zantac can be extremely harmful to the liver for a majority of individuals. It can lead to acute liver damage, ...

Even as GSK defends itself against thousands of personal injury lawsuits relating to its sale of heartburn pill Zantac, a whistleblower lawsuit from the laboratory that first raised alarm bells about ...

Facing tens of thousands of lawsuits over cancer risks on the popular heartburn drug Zantac, GSK has argued there's "no consistent or reliable evidence" that the medicine causes cancer. But a new ...

How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions – with a massive $2.2 billion settlement? The answer appears to lie with the whistleblower suit ...

The drug Zantac can elevate the risk of a person developing cancer. The active ingredient, ranitidine, contains a contaminant called NDMA, which is a probable human carcinogen. The above information ...

(Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused ...

Ohio Attorney General Dave Yost is pushing to lead a class-action lawsuit against a pharmaceutical company. [DOWNLOAD: Free WHIO-TV News app for alerts as news breaks] He is accusing GSK, formerly ...